WallStSmart
KYNB

Kyntra Bio, Inc.

NASDAQ: KYNB · HEALTHCARE · BIOTECHNOLOGY

$7.27
+3.12% today

Updated 2026-04-30

Market cap
$28.37M
P/E ratio
P/S ratio
4.41x
EPS (TTM)
$-14.40
Dividend yield
52W range
$5 – $13
Volume
0.0M

Kyntra Bio, Inc. (KYNB) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
-60.1%
Last 4 quarters
Revenue YoY growth
-101.0%
Most recent quarter
EPS YoY growth
-2050.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-4.6%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-9.9%
2025-11-10
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-17$-3.51+9.7%$7.00$7.05+0.7%
2025-11-10$-3.25-3321.1%$11.03$9.94-9.9%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-3.89$-3.51+9.7%$1.28M-101.0%
2025-09-30$-0.10$-3.25-3321.1%$1.08M-97.7%
2025-06-30$-0.09$-3.39-3666.7%$1.35M+35.1%
2025-03-31$-0.10$0.05+150.0%$2.74M-89.2%
2024-12-31$-0.17$0.18+205.9%$-123.26M-554.2%
2024-09-30$-0.31$-0.17+45.2%$46.33M+15.4%
2024-06-30$-0.32$-0.16+50.0%$998000.00-97.7%
2024-03-31$-0.41$-0.33+19.5%$25.36M-29.9%
2023-12-31$-0.44$-0.57-29.5%$27.14M
2023-09-30$-0.68$-0.65+4.4%$40.13M
2023-06-30$-0.70$-0.90-28.6%$44.32M
2023-03-31$-0.75$-0.81-8.0%$36.16M

Frequently asked questions

Has Kyntra Bio, Inc. beaten earnings estimates?
Kyntra Bio, Inc. has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of -60.1% over the last 4 quarters.
How does KYNB stock react to earnings?
KYNB stock has moved an average of -4.6% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Kyntra Bio, Inc.'s revenue growth rate?
Kyntra Bio, Inc. reported year-over-year revenue growth of -101.0% in its most recent quarter, with EPS growing -2050.0% year-over-year.